Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Delivery
August 06 2018 - 09:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International
Develops
Microemulsion Formulation of
Alpha Lipoic Acid for Intranasal
Delivery
Company Expands Product Pipeline in
Neurodegenerative Arena
Oceanside, CA
-- August
6, 2018 --
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
today successful production
of a stable microemulsion
of Alpha Lipoic
Acid (ALA)
from
ingredients Generally Regarded as Safe (GRAS). The
microemulsion,
which is a form of racemic alpha lipoic
acid containing
microparticles
of
ALA, is
an
ingredient in the Company's
issued U.S. Patent No.:
9,682,047 along with
pterostilbene, the active ingredient
in the Company's patented
ProJuvenol product.
Like
pterostilbene, ALA is
a very
potent
anti-oxidant and
is also known as -lipoic
acid, alpha lipoic acid (ALA) and thioctic acid, an organosulfur
compound derived from octanoic acid and appears to be an ideal
substance in the treatment of oxidative brain and neural disorders
involving free radical processes. Thiols
like
ALA are central to
antioxidant defense in brain and other tissues.
It is believed that
Reactive Oxygen Species (ROS) are involved in many different types
of pathologic conditions in the brain and neural tissue. Brain
disorders involving free radical injury have few
neuropharmacological intervention strategies for treatment of these
conditions. ALA as a potent antioxidant, can regenerate through
redox cycling other potent antioxidants like vitamin C and vitamin
E, and to raise intracellular glutathione levels. The most
important thiol antioxidant, glutathione, cannot be directly
administered, whereas alpha lipoic acid
can.
"There are numerous
publications showing promising effects of alpha lipoic acid in
preclinical models of neurodegenerative conditions such as multiple
sclerosis1,2,
stroke3,4,
and
Alzheimer's
Disease5"
said
James
Veltmeyer, MD, Chief Medical
Officer of Therapeutic Solutions
International. "By providing
alternative delivery mechanisms of this agent, we believe we may be
offering novel approaches towards addressing these terrible
conditions."
"Treatment of chronic
neurodegenerative conditions require a multi-factorial approach
that addresses various molecular pathologies involved in the
condition" added
Tim
Dixon,
CEO of Therapeutic
Solutions International. "By providing novel
formulations capable of augmenting delivery of agents across the
blood brain barrier, we aim to provide physicians new tools in
their arsenal in treatment of conditions such as multiple
sclerosis, Alzheimer's and post-stroke recovery."
About
Therapeutic Solutions International, Inc.
The
Company's corporate website is www.therapeuticsolutionsint.com. Our
new products can be viewed on www.projuvenol.com and products can
be ordered at www.youcanordernow.com.
These Supplement
products have not been evaluated by the United States Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any diseases.
1 Dietrich et al.
Early alpha-lipoic
acid therapy protects from
degeneration of the inner retinal layers and vision loss in an
experimental autoimmune encephalomyelitis-optic neuritis
model. J
Neuroinflammation. 2018 Mar
7;15(1):71. https://www.ncbi.nlm.nih.gov/pubmed/29514678
2
Khalili et
al. Effect of alpha-lipoic
acid on asymmetric
dimethylarginine and disability in multiple
sclerosis patients: A randomized
clinical trial. Electron
Physician. 2017 Jul
25;9(7):4899-4905. https://www.ncbi.nlm.nih.gov/pubmed/28894553
3
Wang et
al. The Role of Alpha-Lipoic
Acid in the
Pathomechanism
of Acute
Ischemic Stroke.
Cell
Physiol
Biochem.
2018 Jul 11;48(1):42-53. https://www.ncbi.nlm.nih.gov/pubmed/29996116
4
Choi et
al. Alpha-lipoic
acid treatment is
neurorestorative and promotes functional recovery after
stroke
in
rats. Mol
Brain.
2015 Feb 11;8:9.
https://www.ncbi.nlm.nih.gov/pubmed/25761600
5
Hager et
al. Alpha-lipoic acid as a
new treatment option for Alzheimer's disease--a 48 months follow-up
analysis. J Neural
Transm
Suppl.
2007;(72):189-93. https://www.ncbi.nlm.nih.gov/pubmed/17982894
Safe Harbor
Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions
International, Inc.
ir@tsoimail.com
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2023 to Mar 2024